Business Description
Cell Biotech Co Ltd
ISIN : KR7049960008
Compare
Compare
Traded in other countries / regions
049960.Korea IPO Date
2002-12-13Description
Cell Biotech Co Ltd is a specialized biotech company. It is engaged in the fermentation and coating technology development as well as manufacturing probiotics and lactic acid bacteria. The key product consists Probiotic DUOLAC, Nutra DUOLAC, LACTOClear, and LAB2PRO. The company distributes its products within domestic market and to overseas markets.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 45.22 | |||||
| Equity-to-Asset | 0.95 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.14 | |||||
| Interest Coverage | 35.44 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 11.16 | |||||
| Beneish M-Score | -2.64 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.9 | |||||
| 3-Year EBITDA Growth Rate | 22.3 | |||||
| 3-Year EPS without NRI Growth Rate | 27.7 | |||||
| 3-Year FCF Growth Rate | -0.6 | |||||
| 3-Year Book Growth Rate | 5 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 84.34 | |||||
| 9-Day RSI | 70.71 | |||||
| 14-Day RSI | 61.93 | |||||
| 6-1 Month Momentum % | 12.55 | |||||
| 12-1 Month Momentum % | -9.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 16.99 | |||||
| Quick Ratio | 16.14 | |||||
| Cash Ratio | 14.59 | |||||
| Days Inventory | 103.13 | |||||
| Days Sales Outstanding | 32.25 | |||||
| Days Payable | 28.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.86 | |||||
| Dividend Payout Ratio | 0.48 | |||||
| Forward Dividend Yield % | 3.86 | |||||
| 5-Year Yield-on-Cost % | 2.77 | |||||
| 3-Year Average Share Buyback Ratio | 1.1 | |||||
| Shareholder Yield % | 3.11 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.46 | |||||
| Operating Margin % | 4.08 | |||||
| Net Margin % | 11.72 | |||||
| FCF Margin % | 11.4 | |||||
| ROE % | 5.81 | |||||
| ROA % | 5.44 | |||||
| ROIC % | 4.38 | |||||
| ROC (Joel Greenblatt) % | 18.4 | |||||
| ROCE % | 6.37 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.36 | |||||
| PE Ratio without NRI | 13.05 | |||||
| Shiller PE Ratio | 6.42 | |||||
| Price-to-Owner-Earnings | 16.72 | |||||
| PS Ratio | 1.56 | |||||
| PB Ratio | 0.75 | |||||
| Price-to-Tangible-Book | 0.76 | |||||
| Price-to-Free-Cash-Flow | 13.74 | |||||
| Price-to-Operating-Cash-Flow | 10.77 | |||||
| EV-to-EBIT | 2.22 | |||||
| EV-to-EBITDA | 1.42 | |||||
| EV-to-Revenue | 0.28 | |||||
| EV-to-FCF | 1.79 | |||||
| Price-to-Projected-FCF | 0.5 | |||||
| Price-to-Median-PS-Value | 0.46 | |||||
| Price-to-Graham-Number | 0.67 | |||||
| Price-to-Net-Current-Asset-Value | 1.11 | |||||
| Price-to-Net-Cash | 1.3 | |||||
| Earnings Yield (Greenblatt) % | 45.01 | |||||
| FCF Yield % | 7.28 | |||||
| Forward Rate of Return (Yacktman) % | 1.19 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cell Biotech Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 53,787.388 | ||
| EPS (TTM) (â‚©) | 921 | ||
| Beta | 0.66 | ||
| Volatility % | 19.72 | ||
| 14-Day RSI | 61.93 | ||
| 14-Day ATR (â‚©) | 328.991986 | ||
| 20-Day SMA (â‚©) | 11810 | ||
| 12-1 Month Momentum % | -9.96 | ||
| 52-Week Range (â‚©) | 10500 - 14590 | ||
| Shares Outstanding (Mil) | 6.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cell Biotech Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cell Biotech Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cell Biotech Co Ltd Frequently Asked Questions
What is Cell Biotech Co Ltd(XKRX:049960)'s stock price today?
The current price of XKRX:049960 is â‚©12300.00. The 52 week high of XKRX:049960 is â‚©14590.00 and 52 week low is â‚©10500.00.
When is next earnings date of Cell Biotech Co Ltd(XKRX:049960)?
The next earnings date of Cell Biotech Co Ltd(XKRX:049960) is .
Does Cell Biotech Co Ltd(XKRX:049960) pay dividends? If so, how much?
The Dividend Yield %  of Cell Biotech Co Ltd(XKRX:049960) is 3.86% (As of Today), Highest Dividend Payout Ratio of Cell Biotech Co Ltd(XKRX:049960) was 0.99. The lowest was 0.11. And the median was 0.27. The  Forward Dividend Yield % of Cell Biotech Co Ltd(XKRX:049960) is 3.86%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers